Table 2 Allo-HSCT characteristics (n = 52).
Characteristics | Number of patients (%) |
|---|---|
Age, recipient at allo-HSCT (median) | 45.5 years (range, 17–67) |
Age, donor at allo-HSCT (median) | 35 years (range, 12–66) |
Sex, donor (Male/Female) | 39 (75.0%)/13 (25.0%) |
Sex mismatched | 27 (51.9%) |
Female to male | 18 (34.6%) |
ABO type | |
Matched | 26 (50.0%) |
Major mismatch | 10 (19.2%) |
Major and minor mismatch | 9 (17.3%) |
Minor mismatch | 7 (13.5%) |
ASCT prior to allo-HSCT | 16 (30.8%) |
Time from ASCT to allo-HSCT (median) | 18.5 months (range, 6.5–44.8) |
Time from diagnosis to allo-HSCT (median) | 27.1 months (range, 6.2–117.7) |
Number of lines prior to allo-HSCT (median) | 4 lines (range, 2–6) |
HCT-CI | |
0–1 | 21 (40.4%) |
2 | 13 (25.0%) |
≥ 3 | 18 (34.6%) |
Disease status at allo-HSCT | |
Complete response | 14 (26.9%) |
Partial response | 16 (30.8%) |
Active disease | 22 (42.3%) |
CMV IgG seropositivity | |
Donor+/Recipient+ | 44 (84.6%) |
Donor−/Recipient+ | 6 (11.5%) |
Donor+/Recipient− | 2 (3.8%) |
Donor−/Recipient− | 0 (0%) |
Degree of HLA match | |
HLA match (8/8) | 29 (55.8%) |
HLA mismatch (≤ 7/8 or less) | 23 (44.2%) |
Donor type | |
MSD | 18 (34.6%) |
Haploidentical | 18 (34.6%) |
URD full matched | 11 (21.2%) |
URD one allele mismatched | 5 (9.6%) |
Conditioning regimen type | |
Myeloablative conditioning | 2 (3.9%) |
Reduced-intensity conditioning | 50 (96.1%) |
GVHD prophylaxis | |
Cyclosporin + methotrexate | 18 (34.6%) |
Tacrolimus + methotrexate | 34 (65.4%) |
CD34 × 106/kg infused (median) | 7.253 (range, 0.777–16.170) |
Median > 20,000/mm3 platelet recovery (median) | 12 days (range, 6–22) |
Median > 500/mm3 neutrophil recovery (median) | 11 days (range, 9–18) |
